DOCSLIB.ORG

CLH Report Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CLH Report Template Committee for Risk Assessment RAC Annex 1 Background document to the Opinion proposing harmonised classification and labelling at EU level of divanadium pentaoxide; vanadium pentoxide EC Number: 215-239-8 CAS Number: 1314-62-1 CLH-O-0000006927-60-01/F The background document is a compilation of information considered relevant by the dossier submitter or by RAC for the proposed classification. It includes the proposal of the dossier submitter and the conclusion of RAC. It is based on the official CLH report submitted to public consultation. RAC has not changed the text of this CLH report but inserted text which is specifically marked as ‘RAC evaluation’. Only the RAC text reflects the view of RAC. Adopted 10 December 2020 P.O. Box 400, FI-00121 Helsinki, Finland | Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu [04.01-ML-009.02] ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON DIVANADIUM PENTAOXIDE; VANADIUM PENTOXIDE ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON DIVANADIUM PENTAOXIDE; VANADIUM PENTOXIDE CLH report Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2 International Chemical Identification: Divanadium pentaoxide EC Number: 215-239-8 CAS Number: 1314-62-1 Index Number: 023-001-00-8 Contact details for dossier submitter: ANSES (on behalf of the French MSCA) 14 rue Pierre Marie Curie F-94701 Maisons-Alfort Cedex [email protected] Version number: 02 Date: August 2019 3 ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON DIVANADIUM PENTAOXIDE; VANADIUM PENTOXIDE CONTENTS 1 IDENTITY OF THE SUBSTANCE ....................................................................................................................... 6 1.1 NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE .............................................................................................. 6 1.2 COMPOSITION OF THE SUBSTANCE ......................................................................................................................... 7 2 SEE SPECIFIC STUDY RECORDS BELOW FOR FURTHER INFORMATION.PROPOSED HARMONISED CLASSIFICATION AND LABELLING .......................................................................................... 10 2.1 PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA .......................... 10 3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING .................................................... 12 4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL ............................................... 12 5 IDENTIFIED USES ............................................................................................................................................... 12 6 DATA SOURCES .................................................................................................................................................. 12 7 PHYSICOCHEMICAL PROPERTIES............................................................................................................... 15 8 EVALUATION OF PHYSICAL HAZARDS ...................................................................................................... 16 9 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION) ............ 17 9.1 SHORT SUMMARY AND OVERALL RELEVANCE OF THE PROVIDED TOXICOKINETIC INFORMATION ON THE PROPOSED CLASSIFICATION(S) ....................................................................................................................................... 18 10 EVALUATION OF HEALTH HAZARDS ......................................................................................................... 22 10.1 ACUTE TOXICITY - ORAL ROUTE ...................................................................................................................... 22 10.1.1 Short summary and overall relevance of the provided information on acute oral toxicity ................... 24 10.1.2 Comparison with the CLP criteria ........................................................................................................ 25 10.1.3 Conclusion on classification and labelling for acute oral toxicity ....................................................... 25 10.2 ACUTE TOXICITY - DERMAL ROUTE ................................................................................................................. 25 10.2.1 Short summary and overall relevance of the provided information on acute dermal toxicity .............. 26 10.2.2 Comparison with the CLP criteria ........................................................................................................ 26 10.2.3 Conclusion on classification and labelling for acute dermal toxicity ................................................... 26 10.3 ACUTE TOXICITY - INHALATION ROUTE ........................................................................................................... 27 10.3.1 Short summary and overall relevance of the provided information on acute inhalation toxicity ......... 29 10.3.2 Comparison with the CLP criteria ........................................................................................................ 30 10.3.3 Conclusion on classification and labelling for acute inhalation toxicity .............................................. 30 10.4 SKIN CORROSION/IRRITATION ......................................................................................................................... 43 10.5 SERIOUS EYE DAMAGE/EYE IRRITATION .......................................................................................................... 43 10.6 RESPIRATORY SENSITISATION ......................................................................................................................... 44 10.6.1 Comparison with the CLP criteria ........................................................................................................ 49 10.6.2 Conclusion on classification and labelling for respiratory sensitisation .............................................. 49 10.7 SKIN SENSITISATION ........................................................................................................................................ 53 10.8 GERM CELL MUTAGENICITY ............................................................................................................................ 53 10.8.1 Short summary and overall relevance of the provided information on germ cell mutagenicity ........... 64 10.8.2 Comparison with the CLP criteria ........................................................................................................ 66 10.8.3 Conclusion on classification and labelling for germ cell mutagenicity ................................................ 68 10.9 CARCINOGENICITY .......................................................................................................................................... 76 10.9.1 Short summary and overall relevance of the provided information on carcinogenicity ....................... 81 10.9.2 Comparison with the CLP criteria ........................................................................................................ 85 10.9.3 Conclusion on classification and labelling for carcinogenicity ............................................................ 87 10.10 REPRODUCTIVE TOXICITY ............................................................................................................................... 95 4 ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON DIVANADIUM PENTAOXIDE; VANADIUM PENTOXIDE 10.10.1 Adverse effects on sexual function and fertility..................................................................................... 95 10.10.2 Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility ............................................................................................................................................... 103 10.10.3 Comparison with the CLP criteria ...................................................................................................... 107 10.10.4 Adverse effects on development .......................................................................................................... 109 10.10.5 Short summary and overall relevance of the provided information on adverse effects on development 117 10.10.6 Comparison with the CLP criteria ...................................................................................................... 119 10.10.7 Adverse effects on or via lactation ...................................................................................................... 122 10.10.8 Short summary and overall relevance of the provided information on effects on or via lactation ..... 126 10.10.9 Comparison with the CLP criteria ...................................................................................................... 128 10.10.10 Conclusion on classification and labelling for reproductive toxicity ................................................. 130 10.11 SPECIFIC TARGET ORGAN TOXICITY-SINGLE EXPOSURE ................................................................................. 151 10.12 SPECIFIC TARGET ORGAN TOXICITY-REPEATED EXPOSURE ............................................................................ 151 10.12.1 Short summary and overall relevance of the provided information on specific target organ toxicity – repeated exposure .................................................................................................................................................
Load more

Recommended publications
  • Vanadium Pentoxide and Other Inorganic Vanadium Compounds
    This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organization, or the World Health Organization. Concise International Chemical Assessment Document 29 VANADIUM PENTOXIDE AND OTHER INORGANIC VANADIUM COMPOUNDS Note that the layout and pagination of this pdf file are not identical to the printed CICAD First draft prepared by Dr M. Costigan and Mr R. Cary, Health and Safety Executive, Liverpool, United Kingdom, and Dr S. Dobson, Centre for Ecology and Hydrology, Huntingdon, United Kingdom Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organization, and the World Health Organization, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals. World Health Organization Geneva, 2001 The International Programme on Chemical Safety (IPCS), established in 1980, is a joint venture of the United Nations Environment Programme (UNEP), the International Labour Organization (ILO), and the World Health Organization (WHO). The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management
    [Show full text]
  • Kinetic Studies of Sodium and Metforminium Decavanadates Decomposition and in Vitro Cytotoxicity and Insulin- Like Activity
    inorganics Article Kinetic Studies of Sodium and Metforminium Decavanadates Decomposition and In Vitro Cytotoxicity and Insulin- Like Activity Aniela M. Silva-Nolasco 1,2, Luz Camacho 2 , Rafael Omar Saavedra-Díaz 1, Oswaldo Hernández-Abreu 1 , Ignacio E. León 3 and Irma Sánchez-Lombardo 1,* 1 Centro de Investigación de Ciencia y Tecnología Aplicada de Tabasco, División Académica de Ciencias Básicas (CICTAT), Universidad Juárez Autónoma de Tabasco, Carretera Cunduacán-Jalpa km. 1 Col. La Esmeralda, Cunduacán 86690, Tabasco, Mexico; [email protected] (A.M.S.-N.); [email protected] (R.O.S.-D.); [email protected] (O.H.-A.) 2 Laboratorio de Nutrición Experimental, Instituto Nacional de Pediatría, Ciudad de Mexico 04530, Mexico; [email protected] 3 Centro de Química Inorgánica CEQUINOR (CONICET, UNLP), Bv 120 1465, La Plata 1900, Argentina; [email protected] * Correspondence: [email protected] Received: 22 October 2020; Accepted: 2 December 2020; Published: 8 December 2020 Abstract: The kinetics of the decomposition of 0.5 and 1.0 mM sodium decavanadate (NaDeca) and metforminium decavanadate (MetfDeca) solutions were studied by 51V NMR in Dulbecco’s modified Eagle’s medium (DMEM) medium (pH 7.4) at 25 ◦C. The results showed that decomposition products 2 4 are orthovanadate [H2VO4]− (V1) and metavanadate species like [H2V2O7] − (V2), [V4O12] − (V4) 5 and [V5O15] − (V5) for both compounds. The calculated half-life times of the decomposition reaction were 9 and 11 h for NaDeca and MetfDeca, respectively, at 1 mM concentration. The hydrolysis products that presented the highest rate constants were V1 and V4 for both compounds.
    [Show full text]
  • PROVISIONAL PEER-REVIEWED TOXICITY VALUES for VANADIUM and ITS SOLUBLE INORGANIC COMPOUNDS OTHER THAN VANADIUM PENTOXIDE (CASRN 7440-62-2 and Others)
    EPA/690/R-09/070F l Final 9-30-2009 Provisional Peer-Reviewed Toxicity Values for Vanadium and Its Soluble Inorganic Compounds Other Than Vanadium Pentoxide (CASRN 7440-62-2 and Others) Derivation of Subchronic and Chronic Oral RfDs Superfund Health Risk Technical Support Center National Center for Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Cincinnati, OH 45268 Commonly Used Abbreviations BMD Benchmark Dose IRIS Integrated Risk Information System IUR inhalation unit risk LOAEL lowest-observed-adverse-effect level LOAELADJ LOAEL adjusted to continuous exposure duration LOAELHEC LOAEL adjusted for dosimetric differences across species to a human NOAEL no-observed-adverse-effect level NOAELADJ NOAEL adjusted to continuous exposure duration NOAELHEC NOAEL adjusted for dosimetric differences across species to a human NOEL no-observed-effect level OSF oral slope factor p-IUR provisional inhalation unit risk p-OSF provisional oral slope factor p-RfC provisional inhalation reference concentration p-RfD provisional oral reference dose RfC inhalation reference concentration RfD oral reference dose UF uncertainty factor UFA animal to human uncertainty factor UFC composite uncertainty factor UFD incomplete to complete database uncertainty factor UFH interhuman uncertainty factor UFL LOAEL to NOAEL uncertainty factor UFS subchronic to chronic uncertainty factor i FINAL 9-30-2009 PROVISIONAL PEER-REVIEWED TOXICITY VALUES FOR VANADIUM AND ITS SOLUBLE INORGANIC COMPOUNDS OTHER THAN VANADIUM PENTOXIDE (CASRN 7440-62-2 and others) Background On December 5, 2003, the U.S. Environmental Protection Agency's (U.S. EPA) Office of Superfund Remediation and Technology Innovation (OSRTI) revised its hierarchy of human health toxicity values for Superfund risk assessments, establishing the following three tiers as the new hierarchy: 1) U.S.
    [Show full text]
  • Studies of Recovery Processes for Western Uranium- Bearing Ores
    STUDIES OF RECOVERY PROCESSES FOR WESTERN URANIUM- BEARING ORES Part VIII EXAMINATION OF CERTAIN ASPECTS OF THE "CARBONATE PROCESSES" AS USED AT MONTICELLO, UTAH By R. S. Lowrie and E:. B. Brown OAK RIDGE NATIONAL LABORATORY Y-12 AREA OPERATED BY CARBIDE AND CARBON CHEMICALS DIVISION UNION CARBIDE AND CARBON CORPORATION OAK RIDGE, TENNESSEE ., Index No. -'----Y::.--'5:..!.7.:::.1'------ Subject Category: Metallurgy Raw­ ·I M9.teria1s STUDIES OF RECOVERY PROCl!SSES FOR limTERN TJRANTUM-BlllARING ORES PART VIII Exam1nation of Certain Aspects of the "Carbonate Processes" as Used at Monticello, Utah R. s. Lowrie K. B. Brown Y-12 ChaRdca1 Research Division Mr. G. H. C1ewett, Division Head OAK RIDGI!: NATIONAL lABORATORY Y - 12 AREA Operated by CARBIDE AND CARBON CHEMICAlS ·DIVISION UNION CARBIDE AND CARBON CORPORATION Oak Ridge, Tennessee Contract No. W-7405-Eng-26 ,v;: ....'"'"' ... >Jm.... _,_:::;:;:::co;w - 2 Index No. Y-571 Metallurg-y-;R;.,a~w:,c-;:;Ma"'te=r"'i7al"s=- Distribution, Series A: No. Copies Atomic Energy Commission, Washington (Jesse Johnson) 2 Atomic Energy Commission, New York (Wilson) 5 Battelle Memorial Institute (Bearse) 1 Dow Chemical Company 1 Massachusetts Institute of Technology (Gaudin) 1 Patent Br'anch, washington 1 Technical Information Branch, ORE 10 U. s. Geological Survey 1 Colorado Area Office (Frank H. MacPherson) 2 Carbide and Carbon Chemicals Division (Y-12 Plant) internal distribution as follows: .Mr. c. E. Center 1 Dr. c. E. larson 1 Dr. A. M. Weinberg 1 Dr. E. D. Shipley 1 .Mr. w. D. Lavers 1 Dr. J. A. Swartout 1 .Mr. c. D.
    [Show full text]
  • Chemical Names and CAS Numbers Final
    Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number C3H8O 1‐propanol C4H7BrO2 2‐bromobutyric acid 80‐58‐0 GeH3COOH 2‐germaacetic acid C4H10 2‐methylpropane 75‐28‐5 C3H8O 2‐propanol 67‐63‐0 C6H10O3 4‐acetylbutyric acid 448671 C4H7BrO2 4‐bromobutyric acid 2623‐87‐2 CH3CHO acetaldehyde CH3CONH2 acetamide C8H9NO2 acetaminophen 103‐90‐2 − C2H3O2 acetate ion − CH3COO acetate ion C2H4O2 acetic acid 64‐19‐7 CH3COOH acetic acid (CH3)2CO acetone CH3COCl acetyl chloride C2H2 acetylene 74‐86‐2 HCCH acetylene C9H8O4 acetylsalicylic acid 50‐78‐2 H2C(CH)CN acrylonitrile C3H7NO2 Ala C3H7NO2 alanine 56‐41‐7 NaAlSi3O3 albite AlSb aluminium antimonide 25152‐52‐7 AlAs aluminium arsenide 22831‐42‐1 AlBO2 aluminium borate 61279‐70‐7 AlBO aluminium boron oxide 12041‐48‐4 AlBr3 aluminium bromide 7727‐15‐3 AlBr3•6H2O aluminium bromide hexahydrate 2149397 AlCl4Cs aluminium caesium tetrachloride 17992‐03‐9 AlCl3 aluminium chloride (anhydrous) 7446‐70‐0 AlCl3•6H2O aluminium chloride hexahydrate 7784‐13‐6 AlClO aluminium chloride oxide 13596‐11‐7 AlB2 aluminium diboride 12041‐50‐8 AlF2 aluminium difluoride 13569‐23‐8 AlF2O aluminium difluoride oxide 38344‐66‐0 AlB12 aluminium dodecaboride 12041‐54‐2 Al2F6 aluminium fluoride 17949‐86‐9 AlF3 aluminium fluoride 7784‐18‐1 Al(CHO2)3 aluminium formate 7360‐53‐4 1 of 75 Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number Al(OH)3 aluminium hydroxide 21645‐51‐2 Al2I6 aluminium iodide 18898‐35‐6 AlI3 aluminium iodide 7784‐23‐8 AlBr aluminium monobromide 22359‐97‐3 AlCl aluminium monochloride
    [Show full text]
  • Toxicological Profile for Vanadium
    TOXICOLOGICAL PROFILE FOR VANADIUM U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 2012 VANADIUM ii DISCLAIMER Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services. VANADIUM iii UPDATE STATEMENT A Toxicological Profile for Vanadium, Draft for Public Comment was released in September 2009. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology and Human Health Sciences (proposed) Environmental Toxicology Branch (proposed) 1600 Clifton Road NE Mailstop F-62 Atlanta, Georgia 30333 VANADIUM iv This page is intentionally blank. VANADIUM v FOREWORD This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.
    [Show full text]
  • Toxicological Profile for Vanadium
    VANADIUM 165 8. REGULATIONS, ADVISORIES, AND GUIDELINES MRLs are substance specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites. ATSDR has derived an acute-duration inhalation MRL of 0.0008 mg vanadium/m3 based on a LOAEL of 0.56 mg vanadium/m3 for lung inflammation in rats exposed to vanadium pentoxide 6 hours/day, 5 days/week for 13 days (NTP 2002). The MRL was derived by dividing the human equivalent concentration of the LOAEL (0.073 mg vanadium/m3) by an uncertainty factor of 90 (3 for use of a minimal LOAEL, 3 for animal to human extrapolation with dosimetric adjustments, and 10 for human variability). 3 ATSDR has derived a chronic-duration inhalation MRL of 0.0001 mg vanadium/m based on a BMCL10 3 of 0.04 mg vanadium/m for degeneration of epiglottis respiratory epithelium of rats exposed to vanadium pentoxide 6 hours/day, 5 days/week for 2 years (NTP 2002). The MRL was derived by dividing the 3 human equivalent concentration of the BMCL10 (0.003 mg vanadium/m ) by an uncertainty factor of 30 (3 for animal to human extrapolation with dosimetric adjustments and 10 for human variability). ATSDR has derived an intermediate-duration oral MRL of 0.01 mg vanadium/kg/day based on a NOAEL of 0.12 mg vanadium/kg/day for hematological and blood pressure effects in humans exposed to vanadyl sulfate for 12 weeks (Fawcett et al.
    [Show full text]
  • IRIS Assessment Plan for Inhalation Exposure to Vanadium and Compounds (Scoping and Problem Formulation Materials)
    EPA/635/R-21/077 IRIS Assessment Plan www.epa.gov/iris IRIS Assessment Plan for Inhalation Exposure to Vanadium and Compounds (Scoping and Problem Formulation Materials) May 2021 Integrated Risk Information System Center for Public Health and Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency IRIS Assessment Plan for Vanadium (Inhalation) DISCLAIMER This document is a public comment draft for review purposes only. This information is distributed solely for the purpose of public comment. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. This document is a draft for review purposes only and does not constitute Agency policy. ii DRAFT DO NOT CITE OR QUOTE ― IRIS Assessment Plan for Vanadium (Inhalation) CONTENTS AUTHORS | CONTRIBUTORS | REVIEWERS .................................................................................................. vi 1. INTRODUCTION ...................................................................................................................................... 1 2. SCOPING AND INITIAL PROBLEM FORMULATION .................................................................................. 3 2.1. BACKGROUND ............................................................................................................................... 3 2.2. SCOPING SUMMARY ....................................................................................................................
    [Show full text]
  • SOLVENT EXTRACTION RECOVERY of VANADIUM (AND URANIUM) from ACID LIQUORS with Dl(2-ETHYLHEXYL) PHOSPHORIC ACID
    <T~ ORNL-2820 Technology-Raw Materials SOLVENT EXTRACTION RECOVERY OF VANADIUM (AND URANIUM) FROM ACID LIQUORS WITH DI(2-ETHYLHEXYL) PHOSPHORIC ACID D. J, Crouse K. B. Brown CENTRAL RESEARCH LIBRARY DOCUMENT COLLECTION LIBRARY LOAN COPY DO NOT TRANSFER TO ANOTHER PERSON If you wish someone else to see this document, send in name vith document and fhe library will arrange a loan. OAK RIDGE NATIONAL LABORATORY operated by UNION CARBIDE CORPORATION for the U.S. ATOMIC ENERGY COMMISSION Printed in USA. Price $2.25 Available from the Office of Technical Services Department of Commerce Washington 25, D.C. LEGAL NOTICE" This report was prepared as on account of Government sponsored work. Neither the United States, nor the Commission, nor any person acting on behalf of the Commission: A. Makes any warranty or representation, expressed or implied, with respect to the accuracy, completeness, or usefulness of the information contained In this report, or that the use of any information, apparatus, method, or process disclosed in this report may not infringe privately owned rights; or B. Assumes any liabilities with respect to the use of, or for damages resulting from the use of any information, apparatus, method, or process disclosed in this report. As used in the above, "person acting on behalf of the Commission'* includes any employee or contractor of the Commission, or employee of such contractor, to the extent that such employee or contractor of the Commission, or employee of such contractor prepares, disseminates, or provides access to, any information pursuant to his employment or contract with the Commission, or his employment with such contractor.
    [Show full text]
  • Vanadyl Sulfate Indicated Effects on Body Weight in Animals While Studies with Sodium Metavanadate Showed Effects on Urinary Markers
    Chemical Information Review Document for Oral Exposure to Tetravalent and Pentavalent Vanadium Compounds Supporting Nomination for Toxicological Evaluation by the National Toxicology Program January 2008 National Toxicology Program National Institute of Environmental Health Sciences National Institutes of Health U.S. Department of Health and Human Services Research Triangle Park, NC http://ntp.niehs.nih.gov/ Abstract Vanadium (CAS No. 7440-62-2) is an element that exists in a number of oxidation states ranging from -1 to +5 and can be found in various locales around the world. Absorption of vanadium from the gastrointestinal tract is poor and most ingested vanadium is typically converted to vanadyl. Excretion of absorbed vanadium is primarily via urine while unabsorbed vanadium is mainly eliminated in feces. Studies indicate that toxicity is dependent on the valence of vanadium, increasing with increasing valence. Thus, pentavalent vanadium is more toxic than tetravalent vanadium. Acute toxicity studies indicate that administration of vanadium compounds is associated with locomotor impairments and effects on respiratory and cardiovascular systems. Short-term studies indicate that while pentavalent vanadium compounds produced effects on a variety of hematological markers, tetravalent compounds do not appear to have similar effects. Both valence states are associated with alterations in body weight, and food and fluid intake after short-term oral administration. Chronic studies with vanadyl sulfate indicated effects on body weight in animals while studies with sodium metavanadate showed effects on urinary markers. A few studies indicated that toxicological effects of vanadium compounds can be modified by the presence of other compounds. Tetravalent vanadium compounds were shown to have impacts on the structures within reproductive organs, survival rate of weanlings, sperm density and motility, fertility, and litter size.
    [Show full text]
  • Systematic Review Protocol for the Vanadium and Compounds (Oral Exposure) IRIS Assessment
    [EPA/635/R-21/047] IRIS Assessment Protocol www.epa.gov/iris Systematic Review Protocol for the Vanadium and Compounds (Oral Exposure) IRIS Assessment (Preliminary Assessment Materials) April 2021 Integrated Risk Information System Center for Public Health and Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Washington, DC Systematic Review Protocol for the Vanadium and Compounds (Oral) IRIS Assessment DISCLAIMER This document is a public comment draft for review purposes only. This information is distributed solely for the purpose of public comment. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. This document is a draft for review purposes only and does not constitute Agency policy. ii DRAFT―DO NOT CITE OR QUOTE Systematic Review Protocol for the Vanadium and Compounds (Oral) IRIS Assessment CONTENTS CONTENTS .................................................................................................................................................... iii AUTHORS | CONTRIBUTORS | REVIEWERS ................................................................................................... ix 1. INTRODUCTION ...................................................................................................................................... 1 2. SCOPING AND INITIAL PROBLEM FORMULATION
    [Show full text]
  • Vanadium Uptake and Toxicity in Plants
    Review Article Published: 23 Nov, 2020 SF Journal of Agricultural and Crop Management Vanadium Uptake and Toxicity in Plants Aryadeep Roychoudhury* Department of Biotechnology, St. Xavier’s College (Autonomous), 30, Mother Teresa Sarani, Kolkata, West Bengal, India Abstract Metal pollution is a global issue in recent times with documented cases of contamination adjacent to mining areas, industries and wastes from agricultural sector. Among all non-essential metals, vanadium is becoming the focus of attention for the environmentalists and plant scientists, since its level in soil, water and atmosphere is gradually increasing day by day, because of several anthropogenic activities, such as burning of fossil fuels, fertilizer and pesticide application and recycling of domestic wastes. Vanadium pentoxide (V2O5) is the most commonly existing and usable form of vanadium, along with ammonium metavanadate (NH4VO3), sodium metavanadate (NaVO3) and sodium orthovanadate (Na3VO4). Because of its mobile nature, vanadium is readily taken up from the soil by the plant roots where it gets immobilized, with only a small fraction being translocated to the above ground organs. Although vanadium, like other trace elements, have been found to stimulate certain physiological processes and improved growth and yield of plants at lower concentrations, its essentiality as minor element is still debated. On the contrary, massive bioaccumulation of vanadium within plant tissues beyond the threshold limit is reported to exert severe consequences like inhibition of growth of plant and plant parts, chlorophyll content and photosynthesis, as well as bringing forth oxidative damages, chromosome breakage and aberrations, disruption in mineral homeostasis and perturbing smooth operation of several metabolic processes.
    [Show full text]